Annual Meeting Presentation

Annual Shareholders
Meeting
Presentation
TruScreen Group Limited
10 September 2020

Introduction of Chief Executive
Officer –Victoria Potarina
⚫Joined TruScreen as CEO as of March 2020;
⚫Over 20 years of experience with major multinational
blue chip companies;
⚫12 year of experience in Medical Device business of
Johnson & Johnson;
⚫International career across Eastern Europe, Russia,
the UK, Ireland, Australia;
⚫Deep expertise in the business model based on sale of
consumables;
⚫Focussed on commercial efficiency and customer
experience;
⚫Masters in App Ling (Hons), GAICD, MBA candidate
with MGSM
2

3
TruScreen Vision: A world without cervical
cancer.
Cervical cancer can and should be prevented.
TruScreen provides an accurate, real-time
screening solution.
Our screening solution is ideal for communities that can’t access
conventional laboratory-enabled screening methods. It is affordable and
easy to learn. Our purpose is to ensure that all women of screening age –
no matter who they are –can have access to quality screening.

Cervical cancer
is a major public health issue
Fourth most common cancer, affecting women
►570,000 new cases p.a.
►311,000 deaths p.a.
Young women in low and middle income
countries (LMIC) are most at risk
►Most diagnoses occur at age 35-44
►85% of cases and 87% of deaths occur in
LMICs
4

WHO Global Targets for 2030 (Draft)
5
The World Health
Organisation has
set a target to
eliminate cervical
cancer
by the end of the
century.
90% coverage of HPV
Vaccination of girls
(by 15 years of age);
70% coverage of
screening (70% of
women are screened with
high performance tests
by the ages of 35 and 45
years) and 90%treatment
of precancerous lesions;
Management of 90% of
invasive cancer cases

TruScreen Presence in biggest Emerging and LMIC markets
6
Women eligible for
targeting in key markets
1bn
In millions
TruScreen’s
current markets
Targeting
commercial roll-out
4
Zimbabwe
Mexico
Vietnam
Russia
Eastern
Europe
IndiaChina
33
24
42
27
318
402

Results FY 31
March 2020

FY 31 March 2020 Highlights
⚫Progress in commercial roll-out with big trials finalized in China, India and Vietnam
⚫Main market continues to be China with over 60% of sales
⚫Initial results from COGA trial in China surpassed expectations (better or equal to LBC and
hrHPVin the same study)
⚫Service centres established in China, Russia and Vietnam
⚫TruScreen cervical cancer screening device acknowledged in Unitaid/WHO report on screening
and treatment technologies and advantages of use in low and middle-income countries
⚫New CEO started as of 2
nd
March
8

FY 31 March 2020 Finance Results
⚫Sales down 31% to NZ$1.3m, from Chinese
procurement delays and initial COVID-19
⚫Total revenue down 18% to NZ$2.55m
⚫EBITDA improvement of 23% YOY with reduction
in overhead costs
⚫China remains primary focus, recent entry into
Vietnam
⚫Improvement in operating cash outflow
⚫Successful capital raise of NZ$5.243m early in the
new year
9
KEY FINANCIALS
NZD (m)
FY 18
Actual
FY 19
Actual
FY 20
Actual
% Change
FY20/FY19
Sales0.81.91.3-31%
Total Revenue2.23.12.5-18%
COGS.741.40.8
R&D1.91.71.1
EBITDA(3.6)(2.8)(2.1)+23%
Net Assets¹11.611.37.2
Cash²1.21.71.0
¹Net assets in 2020 reflects a $2.4m write down of intangible assets.

$0
$500,000
$1,000,000
$1,500,000
$2,000,000
$2,500,000
$3,000,000
$3,500,000
20192020
Total revenue
$1,200,000
$1,230,000
$1,260,000
20192020
R&D Income
$0
$100,000
$200,000
$300,000
$400,000
$500,000
$600,000
$700,000
$800,000
20192020
Device revenue
$0
$200,000
$400,000
$600,000
$800,000
$1,000,000
$1,200,000
$1,400,000
20192020
Consumables (SUS)
Full-Service Distribution Chanel
⚫SUS revenue will grow at a higher rate
thanDevicerevenue
⚫SUSrevenue will become a sustainable
recurring revenue stream
⚫The device has an expected lifetime
of 5-7 years and the SUS is used
once per test per patient
0 yrs.5 yrs.
Device
SUS
DeviceandSUSRevenue
Revenue, $NZ

China: The biggest market with a growing sales trend and
huge potential
FY2020 Market Progress:
⚫Number of installed devices increased by 13% vs LY.
⚫SUS sales increased by 38% in units despite of COVID-19 lockdown since January 2020
⚫Expanded sales network to cover all the major areas in the country
⚫Commenced a large clinical trial project with COGA, aiming to complete by end of December 2020.
Preliminary results are promising
⚫Distributor Sponsored more than 100 conferences/workshops including COGA and CSCCP annual
meetings
11
404m women of screening age. No centralized screening program

RUSSIA: Early commercialisation stage with focus on
clinical education
FY2020 Market Progress:
⚫New highly professional distributor established in 2019.
⚫TruScreen conducted a clinical training program with IMS and KOL in June 2019.
⚫TruScreen completed technical training with IMS, established a local service centre in September
2019.
⚫Commercial sales proceeded in line with 2-year contract.
12
42m women of screening age. No centralized screening program

Clinical studies: China,
Vietnam, India
⚫China –COGA project 1
st
phase completed with a
multi-centre study involving 5 top level teaching
hospitals and 1,022 women, TruScreen performance
proved superior or equal to the LBC and hrHPV
testing.
⚫China –4 separate clinical trials involving total 1,857
women were completed throughout 2019. Results in
line with other studies.
⚫India –at end of 2019 AIIMS (All India Institute of
Medical Sciences) completed a study involving 645
women, demonstrated better sensitivity and specificity
than that of Pap smear.
⚫Vietnam –Hanoi Obstetrics and Gynaecologic
Hospital finished a comparison study in November
2019 confirming TruScreen is a better solution for
cervical cancer screening in Vietnam.
13

Our plans for FY
31 March 2021

TruScreen Path to Growth*
15
2014 Nov
Listing on NZAX
Strengthen / growing team
Recovery COVID-19
Margin improvement
Further roll-out and
manufacture in China
Setting commercial roll-out in
Vietnam and India
2018 Oct
523% sales
growth in H1
2019 May
Recognition by
World Health
Organization
CFDA approval for
second generation
device
2017 Dec
Commence large
scale pilot with China
CDC and COGA
2018 Jul
Migration to NZX
2018 Dec
2019 Sep
China COGA study
first screening
results exceed
expectations
Setting the fundamentals 2014 – 2020
Transformation
2021 – 2022
Rapid Growth 2023 &
beyond
Rapid non-linear sales growth
Company growth to support the sales
Strategic partnerships
* Subject to covid-19 and geopolitical situation

Drive adoption in
established markets
and new markets
►Continue roll-out in more
established markets
(China, Russia,
Zimbabwe)
►Drive adoption in
Vietnam and prepare
roll-out in India based on
successful clinical trials
finalized recently
►Seed in promising LMIC
markets (Eastern
Europe)
Relentless focus on
product quality and
innovation
►New Quality Assurance
(QA) systems
implementation
►Ongoing improvement of
device in line with
feedback from markets
►Innovative approaches to
communication with
customers and doctors,
re-branding.
Expanding clinical
support
►New clinical publications
under MAC supervision
►Continue local trials to
ensure local KOL
support
►Launch online education
module with certification
to prepare the company
for rapid expansion
Enhance team
capabilities
►Hiring of high profile
executives with expertise
in medical devices /
LMIC markets (CEO,
CTO)
►Leverage digital
solutions for QA, training
& education, sales
support
►Grow the team in line
with sales
progress/business needs
4 Business Strategy Pillars -FY 31 March 2021
16

Highlights of FY 31 March 2021 -progress
⚫Sales YTD +69% vs. last year, NZD (April-Aug’19 to April-Aug’20, unaudited)
⚫Sales of SUS +79% YTD vs last year, units (April-Aug’19 to April-Aug’20, unaudited)
⚫Milestone of 100 installed devices achieved (devices that are used for screening in key countries)
⚫Approval from Vietnamese Ministry of Health and roll-out in major Hanoi hospital
⚫Further progress with COGA -over 6,000 women screened
⚫Further progress with clinical educational program in Russia:
●In May 2020 IMS launched a national education campaign, “Women of a different age: from onco-denial
to onco-phobia” featuring TruScreen as the primary screening method. Over 2,800 doctors and
specialists across 18 cities completed the training
●on-line format started, 7 on-line webinars conducted with over 350 doctors educated on-line on benefits
of Truscreenscreening system
⚫Appointment of a specialized medical device distributor for Eastern Europe (Aspironix) to cover 3 countries:
Czech, Slovak and Poland (27m screening population).
17

Number of installed devices on track to double by 31
st
March 2021*
18
March’19
64
March’20
June’20
May’20
July’20March’21
81
88
90
100
160
* Excluding Mexico. Subject to cvoid-19 conditions and geopolitical situation.

Future outlook for FY 31 March 2021
⚫Continue to focus on commercial roll-out in key markets -China
⚫Achieve above 160 installed devices across key markets (+100% YoY)
⚫Obtain COGA consensus in China in cervical cancer screening
⚫Continue with HCP education program in Russia, increase of commercial clinics’ coverage
⚫Roll out commercially in Vietnam and Zimbabwe
⚫To establish a presence in Eastern Europe with 1
st
commercial sales to start in H1CY’21
⚫Roll out of new branding across all communication channels
⚫Enhancing team capabilities in Technology and Medical Affairs groups.
* Subject to covid-19 and geopolitical situation
19

20
Contact us for more information:

21
Disclaimers
ThispresentationhasbeenpreparedbyTruScreenGroupLimited(the“Company”)andisdated10September2020.Thispresentationcontainssummary
informationabouttheCompanyanditsactivitieswhichiscurrentasatthedateofthispresentation.Theinformationinthispresentationisofageneralnatureand
doesnotpurporttobecompletenordoesitcontainalltheinformationwhichaprospectiveinvestormayrequireinevaluatingapossibleinvestmentintheCompany.
ThispresentationshouldbereadinconjunctionwiththeCompany’sannualreport,marketreleasesandotherperiodicandcontinuousdisclosureannouncements,
whichareavailableatwww.nzx.com.Thispresentationdoesnotconstituteanoffer,advertisementorinvitationinanyplaceinwhich,ortoanypersontowhom,it
wouldnotbelawfultomakesuchanoffer,advertisementorinvitation.
Notfinancialproductadvice
ThispresentationisforinformationpurposesonlyandisnotfinancialorinvestmentadviceorarecommendationtoacquiretheCompany’ssecurities,andhasbeen
preparedwithouttakingintoaccounttheobjectives,financialsituationorneedsofprospectiveinvestors.Beforemakinganinvestmentdecision,prospective
investorsshouldconsidertheappropriatenessoftheinformationhavingregardtotheirownobjectives,financialsituationandneedsandconsultafinancialadviser,
solicitor,accountantorotherprofessionaladviserifnecessary.
Pastperformance
Anypastperformanceinformationgiveninthispresentationisgivenforillustrativepurposesonlyandshouldnotberelieduponas(andisnot)anindicationoffuture
performance.Norepresentationsorwarrantiesaremadeastotheaccuracyorcompletenessofsuchinformation.
Futureperformance
Thispresentationincludescertain“forward-lookingstatements”abouttheCompanyandtheenvironmentinwhichtheCompanyoperates.Forward-looking
informationisinherentlyuncertainandsubjecttocontingencies,knownandunknownrisksanduncertaintiesandotherfactors,manyofwhichareoutsideofthe
Company’scontrol,andmayinvolvesignificantelementsofsubjectivejudgementandassumptionsastofutureeventswhichmayormaynotbecorrect.Anumber
ofimportantfactorscouldcauseactualresultsorperformancetodiffermateriallyfromanyforward-lookingstatements.Noassurancecanbegiventhatactual
outcomesorperformancewillnotmateriallydifferfromtheforward-lookingstatements.Theforward-lookingstatementsarebasedoninformationavailabletothe
Companyasatthedateofthispresentation.Exceptasrequiredbylaworregulation(includingtheListingRules),theCompanyundertakesnoobligationtoprovide
anyadditionalorupdatedinformationwhetherasaresultofnewinformation,futureeventsorresultsorotherwise.

Thank you
22